Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences
Dr. Fernando de la Calle holds an Executive MBA (2005) and Ph.D in Molecular Microbiology from the Universidad Autónoma de Madrid (1998). He joined PharmaMar, Spanish company involved in advancing cancer care through the discovery and development of marine derived drugs, in 1988. Since 1999, he has had been Head of the Marine Microbiology R&D Department. The activities of his research group are focused on the study of the marine microorganisms as potential producers of antitumor compounds (drug discovery) and the design of biotechnological processes to supply drug substances. Fernando has been one of the authors of the current manufacturing process of Yondelis, a marine derived compound recently approved by the EMEA (European Union) for the treatment of soft- tissue sarcomas (2007) and recurrent ovarian cancer in combination with Caelyx® (2009).
Microbiology, Cancer and Drug discovery